![]() ![]() ![]() 13 First, although BM is the largest source, BM-derived MSCs may have restricted clinical use because of the invasive procedure required for their isolation, insufficient cell number, and reduced differentiation ability with increasing age. Generally, MSCs derived from these three sources are well-known to express similar surface antigens, whereas their morphology and proliferation rate vary. 11, 12 Among these, three main sources have been demonstrated as capable of treating liver disease: BM-MSCs, UCB-MSCs, and AT-MSCs. MSCs can be isolated from most organs or tissues, including bone marrow (BM), umbilical cord blood (UCB), adipose tissue (AT), peripheral blood, trabecular bone, synovial membrane, cartilage, and muscle. To address this problem, the International Society for Cellular Therapy recommends a set of three criteria to define human MSCs 10 adherence to plastic, specific surface antigen expression, and multipotent differentiation potential ( Table 1). 9 Different investigators define MSC characteristics in varying ways. MSCs can differentiate into either mesodermal or ectodermal cells, resulting in adherent multipotent fibroblast-type stem cells. Definition and sources of MSC transplantation The purpose of this review is to present the therapeutic effects of MSCs in liver diseases to address questions regarding efficacy, safety, and possible risks involved, as well as to discuss recent clinical advances involving clinical MSC-based therapies, opening a new path toward further studies.ġ. Furthermore, MSC transplantation has been considered safe and widely assessed in clinical settings of various diseases with promising results. 7 Additionally, MSCs are safe in terms of ethical concerns because they do not originate from somatic cells. 6 They have self-renewal ability and can differentiate into cells of various lineages, including osteoblasts, adipocytes, and chondrocytes. 4, 5 Of these cell types, MSCs have been shown to have the advantages of being obtained relatively easily and possessing low immunogenicity. Stem cell transplantation including hematopoietic, induced pluripotent, and mesenchymal stem cells (MSCs) can be manipulated for division into hepatocyte-like cells both in vitro and in vivo. Stem cell transplantation has been proposed as a potential strategy for patients with hepatic diseases to prevent progression and treat those with advanced fibrosis. 3 However, transplants are not readily available in many countries, and in countries where transplants are available, organ shortages and high costs related with transplantation make this an impractical option for many patients. 1, 2 The ultimate treatment for end-stage cirrhosis is liver transplantation. All Rights Reserved.Chronic liver injury, such as that arising from viral infection, alcohol abuse, or metabolic diseases, causes liver cirrhosis and failure. Click below to view Liver Cirrhosis patient experiences.Ĭontact Us about Stem Cell Therapy for the Following ConditionsĬopyright Returning Hope Limited. These documents are either written by patients or edited together from comments patients recorded during interviews. These pages detail patients’ treatment journeys, including the condition before treatment, the treatment protocols the received, and after-treatment observations. StemCellsChina hosts patient experience pages from past patients. Stem Cells China Liver Cirrhosis Patient Experience Pages Click the link below to view the Study PDFs in your browser and save it to your computer. Patients’ liver and coagulation function was tested before and after the administering of stem cell therapy. This study was conducted from 2008 to 2009 and focuses on 65 patients receiving Beike Biotechnology stem cells for the treatment of Liver Cirrhosis. UCBSC packets injected by IV and 1-2 interventional injections through hepatic arteryīelow is a link to the Clinical Summary of Stem Cell Therapy for Liver Cirrhosis.Please keep in mind that this is only an example and the injection and cell types may change slightly depending on the patient’s condition. This procedure is minimally invasive and allows for better treatment efficacy.īelow is the general treatment protocol for liver disease. This injection type places the stem cells directly into a target artery through a catheter, allowing the cells access directly to the areas of damage. Patients receiving treatment for this condition not only receive injections of the cell packets by IV but also by intravascular interventional injections. To date, over 70 patients have been treated by our partner for Liver Cirrhosis. Patients Treated by our Partner's Hospitals: over 380 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |